Alembic Pharmaceuticals Ltd banner

Alembic Pharmaceuticals Ltd
NSE:APLLTD

Watchlist Manager
Alembic Pharmaceuticals Ltd Logo
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Watchlist
Price: 764.7 INR 0.7% Market Closed
Market Cap: ₹150.3B

EV/S

2.2
Current
17%
Cheaper
vs 3-y average of 2.7

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
2.2
=
Enterprise Value
₹157.8B
/
Revenue
₹72.7B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
2.2
=
Enterprise Value
₹157.8B
/
Revenue
₹72.7B

Valuation Scenarios

Alembic Pharmaceuticals Ltd is trading below its 3-year average

If EV/S returns to its 3-Year Average (2.7), the stock would be worth ₹919.45 (20% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+62%
Average Upside
34%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 2.2 ₹764.7
0%
3-Year Average 2.7 ₹919.45
+20%
5-Year Average 2.8 ₹956.48
+25%
Industry Average 3.6 ₹1 240.58
+62%
Country Average 2.9 ₹979.87
+28%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
₹157.8B
/
Jan 2026
₹72.7B
=
2.2
Current
₹157.8B
/
Mar 2026
₹74.8B
=
2.1
Forward
₹157.8B
/
Mar 2027
₹82.9B
=
1.9
Forward
₹157.8B
/
Mar 2028
₹91.1B
=
1.7
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
IN
Alembic Pharmaceuticals Ltd
NSE:APLLTD
149.3B INR 2.2 23.9
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 12.9 39.2
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 5.9 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.7 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 5.1 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 5.1 19.5
US
Merck & Co Inc
NYSE:MRK
272.3B USD 4.7 15.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD 108.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 11.1
US
Pfizer Inc
NYSE:PFE
150.6B USD 3.2 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 3.1 16.5
P/E Multiple
Earnings Growth PEG
IN
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Average P/E: 21.8
23.9
20%
1.2
US
Eli Lilly and Co
NYSE:LLY
39.2
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.2
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.5
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.1
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.5
16%
1

Market Distribution

In line with most companies in India
Percentile
41st
Based on 2 864 companies
41st percentile
2.2
Low
0 — 1.6
Typical Range
1.6 — 5
High
5 —
Distribution Statistics
India
Min 0
30th Percentile 1.6
Median 2.9
70th Percentile 5
Max 55 686.2

Alembic Pharmaceuticals Ltd
Glance View

Market Cap
150.3B INR
Industry
Pharmaceuticals

Alembic Pharmaceuticals Ltd., with roots tracing back over a hundred years, began as a modest tincture and alcohol company in Vadodara, India. Its journey from crafting everyday remedies to becoming a stalwart in the pharmaceutical industry exemplifies ambition intertwined with tradition. Today, Alembic stands as a formidable entity, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs) and generic formulations. The company thrives on a blend of innovation and scalability, strategically advancing its manufacturing capabilities while adhering to stringent quality standards. This commitment has not only bolstered its domestic stronghold but also enabled it to penetrate highly regulated international markets, such as the United States and Europe. The company's revenue model is anchored on an extensive portfolio that addresses therapeutic areas ranging from cardiovascular and anti-diabetics to respiratory and anti-infective products. By leveraging its robust R&D infrastructure, Alembic consistently introduces new and complex generics, amplifying its offerings while navigating the generic drug pricing pressures. Their vertically integrated operations ensure cost efficiency and control over API supplies, easing supply chain constraints and fortifying their competitive position. Additionally, strategic partnerships and investments in advanced manufacturing technologies have augmented its capability to meet global demands, cementing Alembic’s reputation as a reliable partner in the pharmaceutical landscape. This multifaceted approach not only expands its business horizons but firmly establishes Alembic as a key player in addressing global healthcare needs.

APLLTD Intrinsic Value
861.77 INR
Undervaluation 11%
Intrinsic Value
Price ₹764.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett